Heart failure with preserved ejection fraction: the impact of stricter definitions

To determine the impact of internationally recognized criteria for the diagnosis of heart failure with preserved ejection fraction (HF‐PEF) on the feasibility of recruitment into a HF‐PEF trial.

[1]  R. Arena,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  Sanjiv J. Shah,et al.  Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.

[3]  M. Voskuil,et al.  Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial , 2013, European journal of heart failure.

[4]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[5]  J. Cleland,et al.  Defining diastolic heart failure and identifying effective therapies. , 2013, JAMA.

[6]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[7]  M. Hori,et al.  Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J‐DHF) , 2013, European journal of heart failure.

[8]  A. Sergeant.  National Heart Failure Audit , 2013 .

[9]  N. Freemantle,et al.  Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study , 2012, European journal of heart failure.

[10]  M. Frenneaux,et al.  Epidemiology and diagnosis of heart failure with preserved left ventricular ejection fraction: rationale and design of the study , 2012, European journal of heart failure.

[11]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[12]  G. Fonarow,et al.  Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE‐US registry and ADHERE‐International registry , 2011, European journal of heart failure.

[13]  W. Paulus,et al.  Treatment of heart failure with normal ejection fraction: an inconvenient truth! , 2010, Journal of the American College of Cardiology.

[14]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[15]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[16]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[17]  S. Solomon,et al.  A clinician's guide to tissue Doppler imaging. , 2006, Circulation.

[18]  J. Cleland,et al.  Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure , 2005, European journal of heart failure.

[19]  U. Dahlström.  Can natriuretic peptides be used for the diagnosis of diastolic heart failure? , 2004, European journal of heart failure.

[20]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[21]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients ≥65 years of age , 2001 .

[22]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. , 2001, The American journal of cardiology.